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Summary: This research paper explores how different drug mechanisms within a 
single class of drugs can produces different profiles of driving impairment. Prior 
research has failed to consider these mechanistic differences and often utilizes 
less controlled study methodologies. The potential impact of differing mechanistic 
effects is important for practitioners but remains unclear for most drugs. Twenty-
nine licensed drivers in good general health completed one of two miniSim™ 
studies using a validated, standardized, driving impairment scenario. Both drugs 
caused degradation in lateral control measures of standard deviation of lane 
position (SDLP) and number of lane departures, however only diphenhydramine 
was found to cause a significant change in steering bandwidth. The studied drugs 
differed in their effects on all longitudinal driving measures with 
diphenhydramine effecting speed and alprazolam effecting the standard deviation 
of speed. Difference in therapeutic mechanism of action results in differing 
pharmacodynamic driving performance outcomes. This analysis reinforces the 
importance of careful consideration of a drug’s specific mechanism of action 
when considering a sedating drug’s impact on a patient’s ability to safely operate 
a motor vehicle. 
 
OBJECTIVES 
 
With almost half of the population of the United States using at least one prescription drug in the 
past month, and over a fifth using at least three in the past month, there is a corresponding rise in 
the number of people driving while under the influence of these medications (National Center for 
Health Statistics., 2014). Many of these drugs may not affect driving performance, however 
some will. There is limited information regarding the pharmacodynamic effects of drugs on 
driving performance, no regulatory requirements to investigate the effects. Since one of the main 
focuses of treatment is to get the patient to a point where they can resume many of their activities 
of daily living (ADLs), it is imperative that practitioners have access to solid evidence-based 
science regarding when a patient may be safe to operate a motor vehicle after consuming a 
potentially impairing substance.  
 
The current body of literature is limited mostly to on-road studies conducted in Europe. While 
these studies are useful, they also have limitations, many of which can be addressed by using an 
advanced research-driving simulator. One of the major limitations is the lack of control over the 
driving environment. Having a sensitive, and repeatable, driving environment is essential to 
getting meaningful findings out of driving studies. On-road studies are unable to ensure exact 
reproduction between trials (ensuring same temperature, weather, state of the road, state of the 
vehicle, etc.). Another limitation is the safety of subjects, staff, and the public when studying 
PROCEEDINGS of the Eighth International Driving Symposium on Human Factors in Driver Assessment, Training and Vehicle Design 
374 
potentially impaired drivers. Simulation using advanced research driving simulators offers a high 
face-validity, reproducible, and safe driving environment to test impairment. 
 
There is currently no standardized or required method to test the potential impairing effects of 
drugs that are active in the central nervous system. These drugs may cause functional changes in 
the brain relative to executive functioning, autonomic functioning (i.e., operational control), 
decision-making, and a number of other skills that are required to safely drive a car. Typically, 
physicians and pharmacists are required to counsel patients on medications that may cause the 
side effects of drowsiness, dizziness or altered mental acuity. This consists of instructing the 
patient that the drug may impair driving performance, and that they should not operate heavy 
machinery until they know how they drug is going to affect them individually.  
 
While drugs may have very different mechanisms of action, the observed impairing effects on 
driving tend to be similar by drug class. Diphenhydramine crosses the blood brain barrier and 
exerts CNS depressant activity causing predictable drowsiness (Gengo et.al., 1988), and the 
accompanying desire to sleep. This effect has been shown to cause significant changes in 
common driving impairment measures - standard deviation of lane position, SD speed, etc. 
(Weiler et al , 2001). 
 
Alprazolam is a short-acting benzodiazepine-class medication that exerts its pharmacologic 
activity by modulating the GABA receptor. The benzodiazepine class of drugs is mainly used to 
control generalized anxiety disorder (though they also have an indication for sleeplessness). In 
treating anxiety, the drug produces a CNS depression that can cause the side effects of 
drowsiness or dizziness. Benzodiazepines have been shown to be associated with an increased 
risk in road-traffic accidents (Barbone et al. 1998), though their effect on individual driving 
performance measures is less clear. 
 
METHODS 
 
Data sources for this analysis come from two different studies completed at the National 
Advanced Driving Simulator (NADS), at the University of Iowa. 20 (12 male, 8 female, mean 
age 25.2yo) subjects participated in a study looking at the effects of alprazolam (Xanax®) on 
driving performance. Subjects were randomized to receive either 1mg alprazolam or a placebo 
(both of which were overencapsulated in identical opaque capsules) in a double-blind placebo 
controlled study design. A separate group of participants (n=9, 3 male, 6 female, mean age 
33.6yo) were enrolled and administered 50mg diphenhydramine (2 tablets of 25mg Benadryl®, 
Johnson & Johnson).  
 
At peak drug effect, subjects in both studies completed a 45min drive through a validated, 
standardized scenario using a NADS miniSim™ research driving simulator. The driving scenario 
has been validated at detecting impairment caused by the consumption of alcohol (Kay et al., 
2013). The scenario incorporates a number of driving speeds and environments including an 
urban environment, a residential area, a high-speed interstate section, and a rural two-lane 
highway all at night. For this analysis, data was used from six driving events with similar driving 
demand: urban driving, suburban driving, interstate curves, rural driving, and rural driving on a 
long curve tangent. 
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Dependent Measures 
Dependent measures in this study were grouped into those related to lateral and those related to 
longitudinal control. Lateral control measures included average lane position relative to the 
center of the lane, standard deviation of lane position (SDLP), bandwidth of the frequency 
content in the steering signal, and number of lane departures per minute. A natural log 
transformation was performed for SDLP. Longitudinal control measures included speed relative 
to the speed limit, standard deviation of speed, percent of time driver was more than 5 mph 
greater than the speed limit, and percent of time driver was more than 5 mph less than the speed 
limit. A Logit transformation was made for both percent measures. 
Participants 
 
Forty-six adult participants in good general health who possessed a valid driver’s license and 
drive at least 5000 miles per year enrolled and completed all study procedures. Participants 
compensated for completion all study procedures.   
 
Apparatus 
 
Driving simulation was carried out in the National Advanced Driving Simulator (NADS) 
miniSim™ Research Driving Simulator (see Figure 1), a PC-based and validated research 
driving simulator (Kay et al., 2013). 
 
 
Figure 1. Three-channel quarter cab miniSim 
 
Experimental Procedures 
 
Participants were recruited for this study using the NADS subject registry and through emails to 
the university community. Individuals who expressed interest were screened over the phone 
including a description of the study and a determination of eligibility. Upon arrival, the study 
was described and participants provided signed informed consent, provided consent of video 
release, and completed a payment voucher for compensation. Subjects then drove a 
familiarization drive to get them acclimated to the driving simulator and also screened for 
simulator sickness. A wellness survey was administered to all participants to assess common 
symptoms of simulator sickness. If no simulator sickness was detected their remaining dosing 
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visits were scheduled. Prior to administration of study drug a urine drug screen, and pregnancy 
test if female, were administered. Once these screening mechanism were completed, the subject 
was ready to start the testing phase of the protocol. In the diphenhydramine arm of the study 
participants drove a baseline study drive prior to drug administration. After completion of the 
baseline drive, they were administered the study drug and waited an hour and fifteen minutes 
until the drug was at peak effect. After this waiting period, the participant was escorted back to 
the driving simulator to complete the study drive under the influence of diphenhydramine. In the 
alprazolam study however, the study drug was administered immediately after morning 
screening, and allowed two hours to take effect. Since this portion of the study was placebo-
controlled, the participant only completed one study drive per visit. Once the study drive was 
complete, all subjects completed a wellness survey to ensure they did not have any simulator 
sickness. After completing all procedures, all subjects driven home by either study staff or a 
friend or relative. 
 
Scenarios 
 
The 35-40 minute driving scenario consisted of three approximate 10-minute segments of urban, 
interstate and rural driving followed by a ten-minute straight rural driving environment. The data 
collection drives started with an urban segment composed of a two-lane roadway through a city 
with posted speed limits of 25 to 45 with signal-controlled and uncontrolled intersections. An 
interstate segment followed that consisted of a four-lane divided expressway with a posted speed 
limit of 70 mph. Following a period in which drivers followed the vehicle ahead, they 
encountered infrequent lane changes associated with the need to pass several slower-moving 
trucks. The drives concluded with a rural segment that was composed of a two-lane undivided 
road with curves, followed by a gravel road segment, and then a 10-minute section of straight 
rural driving. The scenario was designed to provide representative driving environments where 
impaired driving crashes are over represented in the FARS data, but without crash imminent 
events. Three equivalent versions of the scenario were created to minimize learning effects. 
 
RESULTS 
 
The SAS General Linear Models (GLM) procedure was used to perform an Analysis of Variance 
(ANOVA) on the parametric dependent measures. Post-hoc tests were used where appropriate 
for significant main effects and utilized the post-hoc tukey-test. Although event was included in 
the model, only drug effects will be reported. Results are grouped by lateral and longitudinal 
control variables. Cohen’s d effect sizes were calculated for each measure. 
 
For lateral control measures, as can be seen in Table 1, there were significant effects for 
diphenhydramine for SDLP, steering bandwidth and number of lane departures. The table also 
shows that for Alprazolam there are significant effects for SDLP and number of lane departures. 
For both drugs, there was no difference in average lane position. For SDLP and number of lane 
departures the effect size was larger for alprazolam, but for steering bandwidth, there was a small 
effect for Alprazolam but a medium effect for diphenhydramine. A comparison of the means for 
each condition where there was at least one drug effect are provided in Table 2. 
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Table 1. Drug effects on lateral control 
  
Diphenhydramine Alprazolam 
p Cohen's d p Cohen's d 
Average Lane Position 0.4544 0.08 0.3163 0.06 
Standard Deviation of Lane Position 0.0300 0.47 0.0003 0.57 
Steering Bandwidth 0.0289 0.42 0.3216 0.16 
Number of Lane Departures 0.0081 0.38 0.0041 0.60 
 
Table 2. Comparison of mean lateral control performance by drug 
  
Diphenhydramine Alprazolam 
Active Baseline Active Baseline 
Ln Standard Deviation of Lane Position 3.59 3.43 3.60 3.41 
Raw Standard Deviation of Lane Position (cm) 36.4 31.0 36.7 30.2 
Steering Bandwidth (Hz) 1.89 1.74 1.62 1.56 
Number of Lane Departures 1.23 0.80 1.48 0.66 
 
For longitudinal control measures, as can be seen in Table 3 Table 1, there were significant effects 
for diphenhydramine for average speed and for percent speed high. For both effects, the Cohen’s 
d effect size indicates a medium sized effect. The table also shows that for alprazolam there are 
significant effects for standard deviation of speed, but that the effect was small. For both drugs, 
there was no difference in percent speed low. A comparison of the means for each condition 
where there was at least one drug effect are provided in Table 4. 
 
Table 3. Drug effects on longitudinal control 
  
Diphenhydramine Alprazolam 
p Cohen's d p Cohen's d 
Average Speed relative to the Speed Limit 0.0200 0.51 0.1313 0.30 
Standard Deviation of Speed 0.5228 0.14 0.0392 0.19 
Percent Speed High 0.0176 0.43 0.1593 0.18 
Percent Speed Low 0.2732 0.20 0.6774 0.07 
 
Table 4. Comparison of mean longitudinal control performance by drug 
  
Diphenhydramine Alprazolam 
Active Baseline Active Baseline 
Average Speed relative to the Speed Limit (m/s) 1.6 0.6 1.5 0.5 
Standard Deviation of Speed (m/s) 1.8 1.7 2.0 1.8 
Logit Percent Speed High -0.88 -2.82 -2.33 -3.20 
Raw Percent Speed High 40% 26% 33% 25% 
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CONCLUSIONS 
 
Having demonstrated difference in effects between these two CNS depressant drugs, it is useful 
to consider how the different mechanisms of action relate to observed differences. 
Diphenhydramine produced increases in SDLP, lane departures, steering bandwidth, average 
speed, and percentage of time more than 5mph over the speed limit; whereas alprazolam 
produced increases in SDLP, lane departures, and variability in speed. As can be seen both drugs 
resulted in a degradation in lane keeping performance, but only diphenhydramine changed the 
frequency of steering inputs (greater bandwidth). Although both drugs affected speed control, 
diphenhydramine resulted in drivers traveling faster; whereas, alprazolam only increased the 
variability in speed indicating less precise speed maintenance. The mechanisms of these two 
drugs may offer some explanation.  
 
The drowsiness induced by diphenhydramine is most often described as a generalized desire to 
sleep. Individuals on this drug are often very aware of this effect and may be compensating by an 
increased frequency of steering input. This combined with their lack of success at maintaining 
lane position may indicate steering centered on drifts from one side of the lane to the other. The 
greater speed chosen by drivers under the influence of diphenhydramine may also reflect a 
compensatory choice by them to get to the end of the drive sooner, before they fall asleep. In 
contrast, the drowsiness induced by alprazolam is most often described as a general relaxation. 
Individuals on this drug may not be cognizant of the impairing effects while on the drug by 
nature of its therapeutic action (anxiolytic). In this state, these individuals would exhibit less 
compensatory action that results in less precise control consistent with the changes observed.  
 
The fact that two CNS depressant drugs that cause “drowsiness” produce differing impairment 
profiles for driving performance illustrates the importance of a clear understanding of the 
underlying mechanisms associated with the drug’s impairing effects. Understanding these 
differences will help clinicians provide evidence based counseling to their patients. Further 
research is needed to better understand the underlying mechanisms of impairment within and 
across drug classes.  
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